New evidence is tightening links between immune checkpoint inhibitor exposure and patient-level risk. A clinical study/analysis in melanoma associates early cutaneous immune-related adverse events with later multi-organ immune toxicity across thirteen organ systems. In parallel, a pharmacogenomic genome-wide association study in Asian patients flagged a LINC01192 variant (rs146525069) as strongly associated with severe immune-related adverse events during immune checkpoint inhibitor therapy, adding another layer for prospective risk stratification.